TY - JOUR
T1 - The association of late-life diabetes status and hyperglycemia with incident mild cognitive impairment and dementia
T2 - The ARIC study
AU - Rawlings, Andreea M.
AU - Sharrett, A. Richey
AU - Albert, Marilyn S.
AU - Coresh, Josef
AU - Windham, B. Gwen
AU - Power, Melinda C.
AU - Knopman, David S.
AU - Walker, Keenan
AU - Burgard, Sheila
AU - Mosley, Thomas H.
AU - Gottesman, Rebecca F.
AU - Selvin, Elizabeth
N1 - Funding Information:
and with previous brain MRI examinations funded by NHLBI grant R01-HL-70825. Funding for laboratory testing and biospecimen collection at ARIC visit 6 was supported by NIH/ National Institute of Diabetes and Digestive and Kidney Diseases grant R01-DK-089174. M.C.P. was supported by NIH/National Institute on Aging grant R01-AG-057869. Reagents for the 1,5-AG assays were donated by GlycoMark, Inc. Reagents for the GA (albumin) assays were donated by the Asahi Kasei Corporation. Duality of Interest. B.G.W. has previously received reimbursements from Acadia Pharmaceuticals. D.S.K. serves on a Data Safety Monitoring Board for the Dominantly Inherited Alzheimer Network (DIAN) study; is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California; and receives research support from the NIH. No other potential conflicts of interest relevant to this article were reported. Author Contributions. A.M.R., A.R.S., and E.S. designed the study, researched the data, and drafted the manuscript. A.M.R., A.R.S., M.S.A., J.C., B.G.W., M.C.P., D.S.K., K.W., S.B., T.H.M., R.F.G., and E.S. provided interpretation of the data and meaningful contributions and revisions to the manuscript. A.M.R. is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Funding Information:
Acknowledgments. The authors thank the staff and participants of the ARIC Study for the important contributions. Funding. The ARIC Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute (NHLBI) contracts (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, and HHSN268201700004I). Neurocognitive data are collected through National Institutes of Health (NIH) grants 2U01-HL-096812, 2U01-HL-096814, 2U01-HL-096899, 2U01-HL-096902, and 2U01-HL-096917 (from the NHLBI, National Institute of Neurological Disorders and Stroke, National Institute on Aging, and National Institute onDeafnessandOtherCommunicationDisorders)
Publisher Copyright:
© 2019 by the American Diabetes Association.
PY - 2019
Y1 - 2019
N2 - OBJECTIVE We sought to examine associations in older adults among diabetes, glycemic control, diabetes duration, and biomarkers of hyperglycemia with incident mild cognitive impairment (MCI) and incident dementia. RESEARCH DESIGN AND METHODS Weconducted a prospective analysis of 5,099 participants from the Atherosclerosis Risk in Communities (ARIC) Study who attended the fifth (2011-2013) exam. Cognitive status was assessed during follow-up via telephone calls, death certificate codes, surveillance, and a follow-up examination (2016-2017).Wedefined incident cognitive impairment as incident MCI or incident dementia in persons dementiafree at the index examination;wealsoexamined eachoutcomeseparately. Diabetes was defined using self-report, medications, or HbA1c ≥6.5%; poor glycemic control in persons with diabetes was defined as HbA1c ≥7%. We examined the following biomarkers of hyperglycemia: HbA1c, fructosamine, glycated albumin, and 1,5-anhydroglucitol. RESULTS Mean age at baseline was 76 years, 59% were female, and 21% were black. Diabetes (hazard ratio [HR] 1.14 [95% CI 1.00, 1.31]), poor glycemic control in persons with diabetes (HR 1.31 [95% CI 1.05, 1.63]), and longer diabetes duration (≥5 vs. <5 years; HR 1.59 [95% CI 1.23, 2.07]) were significantly associated with incident cognitive impairment. We found a J-shaped association between HbA1c and incident dementia. Glycated albumin and fructosamine were also associated with incident dementia, independently of HbA1c. HbA1c and fructosamine were also associated with incident MCI. CONCLUSIONS Diabetes status, poor glycemic control, and longer diabetes duration were associated with worse cognitive outcomes over a median follow-up of 5 years.
AB - OBJECTIVE We sought to examine associations in older adults among diabetes, glycemic control, diabetes duration, and biomarkers of hyperglycemia with incident mild cognitive impairment (MCI) and incident dementia. RESEARCH DESIGN AND METHODS Weconducted a prospective analysis of 5,099 participants from the Atherosclerosis Risk in Communities (ARIC) Study who attended the fifth (2011-2013) exam. Cognitive status was assessed during follow-up via telephone calls, death certificate codes, surveillance, and a follow-up examination (2016-2017).Wedefined incident cognitive impairment as incident MCI or incident dementia in persons dementiafree at the index examination;wealsoexamined eachoutcomeseparately. Diabetes was defined using self-report, medications, or HbA1c ≥6.5%; poor glycemic control in persons with diabetes was defined as HbA1c ≥7%. We examined the following biomarkers of hyperglycemia: HbA1c, fructosamine, glycated albumin, and 1,5-anhydroglucitol. RESULTS Mean age at baseline was 76 years, 59% were female, and 21% were black. Diabetes (hazard ratio [HR] 1.14 [95% CI 1.00, 1.31]), poor glycemic control in persons with diabetes (HR 1.31 [95% CI 1.05, 1.63]), and longer diabetes duration (≥5 vs. <5 years; HR 1.59 [95% CI 1.23, 2.07]) were significantly associated with incident cognitive impairment. We found a J-shaped association between HbA1c and incident dementia. Glycated albumin and fructosamine were also associated with incident dementia, independently of HbA1c. HbA1c and fructosamine were also associated with incident MCI. CONCLUSIONS Diabetes status, poor glycemic control, and longer diabetes duration were associated with worse cognitive outcomes over a median follow-up of 5 years.
UR - http://www.scopus.com/inward/record.url?scp=85068547630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068547630&partnerID=8YFLogxK
U2 - 10.2337/dc19-0120
DO - 10.2337/dc19-0120
M3 - Article
C2 - 31221696
AN - SCOPUS:85068547630
SN - 0149-5992
VL - 42
SP - 1248
EP - 1264
JO - Diabetes care
JF - Diabetes care
IS - 7
ER -